Previously, a higher rate of FGFR1 amplification was reported in invasive breast carcinoma relative to ductal carcinoma in situ, particularly in high grade tumors (27) with FGFR1 amplification present in up to 14% of breast cancer patients (16, 28). Here, FGFR1 is linked to breast carcinoma.